Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul Universitesi School of Medicine, Izmir, Turkey.
J Rheumatol. 2012 Mar;39(3):594-9. doi: 10.3899/jrheum.111073. Epub 2012 Jan 15.
To evaluate the profiles of endothelial microparticles (EMP) and platelet microparticles (PMP) in men with ankylosing spondylitis (AS) and healthy subjects. We also aimed to determine whether microparticles (MP) correlate with disease activity, function, and spinal mobility indices.
There were 82 men with AS and 53 healthy controls. Subjects with a history of chronic diseases including coronary artery disease, hypertension, diabetes mellitus, and dyslipidemia were excluded. MP were stained with monoclonal antibodies against platelets and endothelial cells and quantified using flow cytometry. MP that were positive for both CD42a+/CD31+ and total CD42a+ were identified as PMP; and MP consisting of CD42a-/CD31+ and total CD144+ were considered EMP.
EMP and PMP were similar between the patient and control groups (p > 0.05). Comparison of patients with AS in the active disease state (BASDAI ≥ 4) and in the inactive state showed that EMP and PMP were not different between the groups (p > 0.05). Correlation analysis revealed no correlation with Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, or Bath Ankylosing Spondylitis Metrology Index. C-reactive protein was significantly correlated with PMP and CD42a-/CD31+ EMP (p < 0.05). Comparison of patients with AS treated with anti-tumor necrosis factor (anti-TNF) drugs, subjects treated conventionally, and healthy controls revealed that PMP and CD42a-/CD31+ EMP were significantly downregulated in patients receiving biological agents.
Circulating EMP and PMP, known to be indicators and mediators of vascular injury, were not significantly altered in men with AS who did not have classical cardiovascular risk factors. Significantly downregulated MP in patients receiving biological agents suggested that anti-TNF treatment may have a beneficial effect on vascular function in AS.
评估强直性脊柱炎（AS）男性患者和健康对照者内皮细胞微颗粒（EMP）和血小板微颗粒（PMP）的特征。我们还旨在确定微颗粒（MP）是否与疾病活动度、功能和脊柱活动度指数相关。
共纳入 82 例 AS 男性患者和 53 例健康对照者。排除有慢性疾病史（包括冠心病、高血压、糖尿病和血脂异常）的患者。用针对血小板和内皮细胞的单克隆抗体对 MP 进行染色，并使用流式细胞术进行定量。CD42a+/CD31+和总 CD42a+均阳性的 MP 被鉴定为 PMP；而 CD42a-/CD31+和总 CD144+的 MP 被认为是 EMP。
患者组和对照组的 EMP 和 PMP 相似（p＞0.05）。比较处于活动期疾病状态（BASDAI≥4）和非活动期疾病状态的 AS 患者，发现两组间 EMP 和 PMP 无差异（p＞0.05）。相关性分析显示，EMP 和 PMP 与 Bath 强直性脊柱炎疾病活动指数、Bath 强直性脊柱炎功能指数或 Bath 强直性脊柱炎计量学指数均无相关性。C 反应蛋白与 PMP 和 CD42a-/CD31+ EMP 显著相关（p＜0.05）。比较接受抗肿瘤坏死因子（anti-TNF）药物治疗的 AS 患者、常规治疗的患者和健康对照者，发现接受生物制剂治疗的患者 PMP 和 CD42a-/CD31+ EMP 显著下调。
在未发生经典心血管危险因素的 AS 男性患者中，循环 EMP 和 PMP 作为血管损伤的标志物和介质，并未显著改变。接受生物制剂治疗的患者 MP 显著下调提示 anti-TNF 治疗可能对 AS 患者的血管功能具有有益作用。
